Obeticholic Acid Ameliorates Non-Alcoholic Fatty Liver Disease By Improving Metabolic Profile In Dietary Obesity, But Not In Obese, Diabetic Foz/Foz Mice

Abstract

Background and Aims: The semi-synthetic farnesoid X receptor (FXR) agonist obeticholic acid (OCA) improves steatosis in patients with non-alcoholic steatohepatitis (NASH), but protective mechanisms remain unresolved. NASH is the outcome of complex interactions between nutrient supply, blood glucose, and adipose lipid storage capacity reflected by adipose morphology and inflammation. We therefore investigated the effects of OCA on glucose metabolism, adipose depots and liver in atherogenic dietfed wildtype (Wt) mice which develop dietary obesity, and Alms1 mutant (foz/foz) hyperphagic mice which develop metabolic obesity with diabetes. Show more